Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

20 Mar 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Staphylococcus Aureus Endocarditis · Phase 4 · Enrollment 300 · Sponsor: Todd C. Lee MD MPH FIDSA

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Critical Care on 20 Mar 2026. The item focuses on Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia. Open the detail page to review the full original feed content.